in order to achieve the above mentioned objectives and in accordance with the purpose of the invention as embodied and broadly described herein , there is provided a process for the synthesis of compound of formula i , as show in schemes i and ii . the starting materials for scheme i and scheme ii may be suitably adapted to produce the more specific compounds of formula i . in scheme i , there is provided a process for preparing a compound of formula x ( formula i , when ar is phenyl or a substituted phenyl having one to three substituents independently selected from halogen ( chlorine , fluorine , bromine , iodine ), nitro , cyano , lower ( c 1 - 4 ) alkyl , lower ( c 1 - 4 ) alkoxy , perhalo lower ( c 1 - 4 ) alkyl or perhalo lower ( c 1 - 4 ) alkoxy ; five to seven membered heterocyclic ring containing one to four heteroatoms selected from the group consisting of oxygen , nitrogen and sulphur , the more preferred ar is 2 , 4 - difluorophenyl ; r 1 and r 2 are independently selected from the group consisting of hydrogen , straight chain or branched alkyl groups having 1 to 3 carbon atoms for example methyl , ethyl , propyl or isopropyl and their combinations thereof ; the preferred alkyls are methyl and ethyl ; the more preferred combination is when r 1 is methyl and r 2 is hydrogen ; y is ch or n ; x is selected from s , o , ch — no 2 , and n — cn ; a is hydrogen , unsubstituted or substituted lower ( c 1 - 10 ) alkyl , said substituents being halogen ( fluorine , chlorine , bromine or iodine ), hydroxy , lower ( c 1 - 4 ) alkoxy , lower ( c 1 - 4 ) perhaloalkyl , lower ( c 1 - 4 ) perhaloalkoxy ; optionally substituted naphthyl ; unsubstituted or substituted aromatic or non aromatic 5 - 6 membered rings with or without one to four heteroatoms independently selected from the group consisting of oxygen , nitrogen and sulphur , said substituents independently selected from one or more groups such as halogen ( fluorine , chlorine , bromine or iodine ), nitro , cyano , hydroxy , lower ( c 1 - 4 ) alkyl , lower ( c 1 - 4 ) alkoxy , lower ( c 1 - 4 ) perhaloalkyl , lower ( c 1 - 4 ) perhaloalkoxy , br 3 , substituted or unsubstituted five or six membered heterocyclic ring systems containing one to four heteroatoms selected from the group consisting of oxygen , nitrogen and sulphur , said heterocycylic substituents being ( c 1 - c 8 ) alkanoyl , lower ( c 1 - c 4 ) alkyl , lower ( c 1 - c 4 ) alkoxy carbonyl , n lower ( c 1 - c 4 ) alkylaminocarbonyl , n , n - dilower ( c 1 - c 4 ) alkylaminocarbonyl , n - lower ( c 1 - c 4 ) alkylaminothiocarbonyl , n , n - di ( lower alkyl )( c 1 - c 4 ) aminothiocarbonyl , n - lower ( c 1 - c 4 ) alkyl sulphonyl , phenyl substituted lower ( c 1 - c 4 ) alkyl sulphonyl , n - lower ( c 1 - c 4 ) alkyl amino , n , n - di ( lower alkyl )( c 1 - c 4 ) amino , unsubstituted or substituted phenyl , said substituents being halogen ( fluorine , chlorine , bromine or iodine ), hydroxy , lower ( c 1 - 4 ) alkoxy , lower ( c 1 - 4 ) perhaloalkyl , lower ( c 1 - 4 ) perhaloalkoxy , nitro , cyano , amino , n ( r 4 ) 2 , 5 - 6 membered heterocyclic rings , the preferred heterocycles being 1 , 3 - imidazolyl ; 1 , 2 , 4 triazolyl ; — chr 5 r 6 ; wherein r 3 is a five or six membered aromatic or non aromatic ring with or without heteroatoms ( oxygen , nitrogen and sulphur ); b is independently selected from ( ch 2 ) m , — o ( ch 2 ) m , — s ( ch 2 ) m ; m is an integer from 1 to 4 ; r 4 is hydrogen , unsubstituted or substituted lower ( c 1 - 4 ) alkyl ; r 5 is — coq , where q = or 4 , — n ( r 4 ) 2 ; r 6 is independently selected from hydrogen , straight chain or branched alkyl with or without substituents , said substituents being halogen ( fluorine , chlorine , bromine or iodine ), hydroxy , lower ( c 1 - 4 ) alkyl , lower ( c 1 - 4 ) alkoxy , lower ( c 1 - 4 0 perhaloalkyl , lower ( c 1 - 4 ) perhaloalkoxy , sr 4 ; phenyl or phenyl substituted with halogen ( fluorine , chlorine , bromine or iodine ), hydroxy , lower ( c 1 - 4 ) alkoxy , lower ( c 1 - 4 ) perhaloalkyl , lower ( c 1 - 4 ) perhaloalkoxy , sr 4 ; heterocyclic rings or substituted heterocyclic rings with heteroatoms selected from oxygen , nitrogen and sulphur , substituents on heterocyclic rings are independently selected from halogen ( fluorine , chlorine , bromine or iodine ), hydroxy , lower ( c 1 - 4 ) alkyl , lower ( c 1 - 4 ) alkoxy , lower ( c 1 - 4 ) perhaloalkyl , lower ( c 1 - 4 ) perhaloalkoxy , sr 4 ; the preferred heterocyclic rings are imidazole and indole ; r 7 is h or selected from the group consisting of r 8 is independently selected from hydrogen , unsubstituted or substituted lower ( c 1 - 4 ) alkyl , aralkyl , aromatic or non aromatic 5 - 6 membered rings with or without one to four heteroatoms selected independently from the group consisting of oxygen , nitrogen and sulphur , which comprises the conversion of the epoxy alcohol of formula ii to the corresponding triflate derivatives with trifluoromethane sulphonic anhydride ( tf 2 o ) in the presence of hunig &# 39 ; s base i . e . n , n - diisopropyl ethylamine , which is further subjected to nucleophilic substitution with t - butyl carbazate to afford substituted hydrazine of the formula iii with inversion of configuration at c - 1 , which on reaction with compound of formula iv in the presence of a base gave epoxide ring opened intermediate of the formula v which is then treated with a compound of the formula vi to give boc protected semicarbazide or thiosemicarbazide derivatives of the formula vii which is further deprotected using trifluoroacetic acid to give the free amine of formula viii which may be treated with a compound of formula ix to give a compound of formula x ( formula i , when the starting compound of formula ii can be prepared by the process as described in u . s . pat . no . 6 , 133 , 485 . the conversion of a compound of formula ii to the compound of formula iii is carried out in a solvent selected from the group consisting of chloroform , dichloromethane , dichloroethane , tetrahydrofuran , and the like . the reaction may be carried out in the presence of a base selected from the group consisting of triethylamine , hunig &# 39 ; s base , pyridine etc . the reaction temperature may range from − 78 ° c . to 40 ° c . the nucleophilic epoxide ring opening of the compound of formula iv may be carried out in the presence of a base such as potassium carbonate , cesium carbonate , calcium carbonate , sodium hydride , and the like . the reaction may be carried out in a solvent selected from the group consisting of dimethylformamide , dimethylsulfoxide , tetrahydrofuran , benzene , toluene , and the like or mixture ( s ) thereof . the reaction temperature may range from about 200 to 120 ° c ., preferably at a temperature in the range of 80 - 85 ° c . the reaction of the compound of formula v with a compound of formula vi to give a compound of formula vii , is carried out in an organic solvent that can be selected from the group consisting of chloroform , dichloromethane , dichloroethane and tetrahydrofuran at a temperature ranging from about 40 - 90 ° c . the deprotection of the boc group in compound of formula vii to give the free amine of formula vii may be carried in an organic solvent such as chloroform , dichloromethane , dichloroethane , tetrahydrofuran , and the like at a temperature ranging from about 0 - 5 ° c . in the presence of trifluoroacetic acid . the reaction of compound of formula viii with a compound of formula ix to give the compound of formula x may be carried out in an organic solvent such as chloroform , dichloromethane , dichloroethane and tetrahydrofuran . the reaction temperature may range from about 0 ° c . to room temperature . scheme ii shows the synthesis of compounds of formula xiii ( formula i , when in which ar , y , r 1 , r 2 , w and a have the same meaning as defined earlier , which comprises treating the compound of formula v with the isothiocyanate of formula xi ( formula vi ; x ═ s ) and the resulting boc derivatives of formula xii ( formula vii ; x ═ s ) is further refluxed to give the desired compound of formula xiii ( formula i , when ( formula viii , x ═ s ) obtained by treating the compound of formula xii with trifluoroacetic acid , upon refluxing , also gives the compound of formula xiii . the reaction of the compound of formula v with the isothiocyanate of formula xi may be carried out in an organic solvent such as chloroform , dichloromethane , dichloroethane tetrahydrofuran , and the like . the reaction temperature may range from about 40 - 90 ° c . the deprotection of the boc group in compound of formula xii is carried out in the presence of an organic solvent selected from the group consisting of chloroform , dichloromethane , dichlorothane and tetrahydrofuran in the presence of trifluoroacetic acid . the ring cyclization of the compound of formula xii or its free amine of formula xiv is carried out using formic acid at a temperature ranging from about 80 - 120 ° c . in the above schemes , where specific bases , solvents , deprotecting agents etc . are mentioned , it is to be understood that other bases , solvents , deprotecting agents etc . known to those skilled in the art may also be used . similarly , the reaction temperature and duration of the reactions may be adjusted according to the desired needs . the intermediates of formula iii , v , vii and viii are new and therefore they also constitute a further object of the invention . these intermediates are highly versatile and can be converted to a multitude of potential antifungal compounds . the invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be constrained to limit the scope of the invention . in a dry 500 ml 3 neck round - bottom flask equipped with a nitrogen inlet , guard tube , addition funnel and a septum were placed the epoxy alcohol ( 10 g ), hunig &# 39 ; s base ( 19 ml ), and dichloromethane ( 60 ml ). the mixture was cooled to − 78 ° c . and trifluoromethanesulfonic anhydride ( 8 . 95 ml ) was added dropwise . after the completion of addition , the reaction mixture was stirred at − 78 ° c . for 30 minutes and at − 20 ° c . for another 30 minutes . a solution of t - butyl carbazate ( 13 g ) in tetrahydrofuran ( 30 ml ) was then added to the above . the reaction mixture was further stirred at this temperature for 2 hours followed by stirring at room temperature for 18 hours . tetrahydrofuran was evaporated and residue taken up in dichloromethane ( 150 ml ). the organic layer was washed with water , brine and dried over sodium sulphate . the solvent was evaporated in vacuo and the residue was purified through column chromatography ( silica gel , 100 - 200 mesh , 6 : 4 dcm : hexane ) to afford the title compound ( 9 . 65 g , 61 %). 1 h nmr ( 300 mhz , cdcl 3 ): δ 1 . 07 ( d , j = 6 . 7 hz , 3h ), 1 . 46 ( s , 9h ), 2 . 79 ( d , j = 5 hz , 1h ), 3 . 08 ( d , j = 5 hz , 1h ), 3 . 22 ( q , j = 6 . 7 hz , 1h ), 5 . 97 ( s , 1h ), 6 . 19 ( s , 1h ), 6 . 76 - 6 . 90 ( m , 2h ), 7 . 35 - 7 . 43 ( m , 1h ). to a solution of epoxide ( 9 . 86 g ) obtained in the previous step and 1 , 2 , 4 - triazole ( 4 . 3 g ) in dry n , n - dimethylformamide ( 50 ml ) was added anhydrous k 2 co 3 ( 8 . 6 ) under nitrogen atmosphere . the reaction mixture was stirred at 40 ° c . for 15 hours and then at 70 ° c . for 4 hours . after the completion of reaction , the reaction mixture was poured in ice cold water ( 500 ml ) and the organic layers were extracted into ethyl acetate ( 3 × 100 ml ). the combined organic layers were washed with water , brine and dried over na 2 so 4 . the solvent was removed in vacuo and the residue obtained was purified through column chromatography ( silica gel , 100 - 200 mesh , 20 % etoac - dcm ) to afford the title compound ( 7 g ). 1 h nmr ( 300 mhz , cdcl 3 ): δ 0 . 91 ( d , j = 6 . 7 hz , 3h ), 1 . 48 ( s , 9h ), 3 . 52 ( q , j = 6 . 7 hz , 1h ), 4 . 75 - 4 . 90 ( m , 3h ), 6 . 2 ( s , 1h ), 6 . 70 - 6 . 77 ( m , 2h ), 7 . 33 - 7 . 41 ( m , 1h ), 7 . 73 ( s , 1h ), 7 . 90 ( s , 1h ). to a solution of the amine ( 6 . 31 g ) obtained in step ( b ) in 1 , 2 - dichloroethane ( 30 ml ) was added 4 -[ 2 , 2 , 3 , 3 - tetrafluoropropoxy ]- phenylisothiocyanate and the mixture refluxed for 12 hours . after the completion of reaction , the solvent was evaporated and the residue obtained was purified through column chromatography ( silicagel , 100 - 200 mesh , 10 % etoac - dcm ) to afford the title compound ( 7g , 78 %). 1 h nmr ( 300 mhz , cdcl 3 ): δ 1 . 05 ( d , j = 6 . 6 hz , 3h ), 1 . 51 ( s , 9h ), 4 . 35 ( t , j = 11 . 7 hz , 2h ), 4 . 44 ( d , j = 14 . 5 hz , 1h ), 5 . 55 ( d , j = 14 . 3 hz , 1h ), 5 . 82 ( s , 1h ), 6 . 07 ( tt , j = 53 . 1 and 4 . 9 hz , 1h ), 6 . 74 - 6 . 79 ( m , 3h ), 6 . 93 - 6 . 96 ( d , j = 8 . 8 hz , 2h ), 7 . 36 - 7 . 39 ( d , j = 8 . 8 hz , 2h ), 7 . 79 ( s , 1h ), 7 . 81 ( s , 1h ), 8 . 51 ( brs , 1h ). the illustrative list of the compounds of the invention which were synthesized by the above method is given below : δ : 1 . 06 ( 3h , d , j = 6 . 1 hz ), 1 . 52 ( 9h , s ), 4 . 44 ( 1h , d , j = 15 . 4 hz ), 5 . 56 ( 1h , d , j = 16 . 9 hz ), 5 . 83 ( 1h , s ), 6 . 75 - 6 . 81 ( 3h , m ), 7 . 06 - 7 . 11 ( 2h , m ), 7 . 33 - 7 . 43 ( 3h , m ), 7 . 81 ( 2h , m ), 8 . 52 ( 1h , brs ). δ : 1 . 05 ( 3h , d , j = 6 . 7 hz ), 1 . 51 ( 9h , s ), 4 . 41 ( 1h , d , j = 14 . 3 hz ), 5 . 55 ( 1h , d , j = 13 . 5 hz ), 5 . 84 ( 1h , brs ), 6 . 69 - 6 . 76 ( 3h , m ), 6 . 86 - 6 . 94 ( 2h , m ), 7 . 29 - 7 . 37 ( 1h , brm ), 7 . 79 ( 1h , brs ), 7 . 81 ( 1h , brs ), 7 . 9 ( 1h , brs ), 8 . 4 ( 1h , brs ). δ : 0 . 92 ( 3h , d , j = 6 . 8 hz ), 1 . 51 ( 9h , s ), 4 . 43 ( 1h , d , j = 14 . 4 hz ), 5 . 53 ( 1h , d , j = 13 . 9 hz ), 5 . 88 ( 1h , s ), 6 . 73 - 6 . 8 ( 3h , m ), 7 . 33 - 7 . 35 ( 1h , m ), 7 . 62 - 7 . 7 ( 4h , m ), 7 . 81 ( 2h , s ), 8 . 75 ( 1h , brs ). δ : 1 . 04 ( 3h , d , j = 6 . 9 hz ), 1 . 5 ( 3h , s ), 3 . 8 ( 3h , s ), 3 . 81 ( 3h , s ), 4 . 43 ( 1h , d , j = 14 . 5 hz ), 5 . 61 ( 1h , d , j = 13 . 9 hz ), 5 . 72 ( 1h , s ), 6 . 49 - 6 . 54 ( 2h , m ), 6 . 71 - 6 . 80 ( 3h , m ), 7 . 29 - 7 . 37 ( 1h , m ), 7 . 78 ( 1h , s ), 7 . 80 ( 1h , s ), 8 . 19 ( 1h , d , j = 8 . 2 hz ), 8 . 8 ( 1h , s ) δ : 1 . 06 ( 3h , d , j = 5 . 9 hz ), 1 . 48 ( 9h , s ), 3 . 6 ( 1h , d , j = 11 . 2 hz ), 3 . 87 - 3 . 93 ( 1h , m ), 4 . 34 . 8 ( brm , 1h ), 5 . 59 ( 1h , d , j = 14 . 4 hz ), 6 . 72 - 6 . 8 ( 3h , m ), 7 . 05 - 7 . 08 ( 2h , m ), 7 . 31 - 7 . 37 ( 3h , m ), 7 . 83 ( 2h , brs ), 8 . 75 ( 1h , brs ). 1 h nmr ( cdcl 3 ): δ 1 . 08 ( d , j = 6 . 41 hz , 3h , chch 3 ), 1 . 53 ( bs , 9h , boc — h ), 4 . 44 ( d , j = 14 . 43 hz , 1h , ch 2 - triazole ), 5 . 56 ( d , j = 14 . 40 hz , 1h , ch 2 - triazole ), 5 . 88 ( bs , 1h , d 2 o - exchangeable , — oh ), 6 . 75 - 6 . 83 ( m , 3h , 2h of arf 2 and 1h of chch 3 ), 7 . 24 - 7 . 28 ( m , 2h arocf 3 — h ), 7 . 32 - 7 . 40 ( m , 1h arf 2 — h ), 7 . 55 ( d , j = 8 . 71 hz 2h , 2h of arocf 3 ), 7 . 81 ( s , 1h , triazole - h ), 7 . 83 ( s , 1h , triazole - h ), 8 . 64 ( bs , 1h , d 2 o - exchangeable , — nh ) δ : 1 . 06 ( 3h , d , j = 6 . 5 hz ), 1 . 51 ( 9h , s ), 4 . 42 ( 1h , d , j = 14 . 3 hz ), 5 . 50 ( 1h , d , j = 13 . 6 hz ), 5 . 93 ( 1h , s ), 6 . 74 - 6 . 82 ( 3h , m ), 7 . 30 - 7 . 38 ( 1h , m ), 7 . 80 - 7 . 83 ( 4h , m ), 8 . 23 ( 1h , s ), 8 . 26 ( 1h , s ), 8 . 92 ( 1h , s ). δ : 1 . 07 ( 3h , d , j = 6 . 5 hz ), 1 . 52 ( 9h , s ), 4 . 45 ( 1h , d , j = 14 . 3 hz ), 5 . 52 ( 1h , d , j = 13 . 9 hz ), 5 . 91 ( 1h , s ), 6 . 76 - 6 . 82 ( 3h , m ), 7 . 31 - 7 . 39 ( 1h , m ), 7 . 70 - 7 . 90 ( 6h , m ), 8 . 80 ( 1h , s ), 9 . 0 ( 1h , s ). δ : 1 . 07 ( 3h , d , j = 6 . 5 hz ), 1 . 52 ( 9h , s ), 4 . 46 ( 1h , d , j = 14 . 4 hz ), 5 . 55 ( 1h , d , j = 14 . 6 hz ), 5 . 89 ( s , 1h ), 6 . 74 - 6 . 82 ( 3h , m ), 7 . 34 - 7 . 39 ( 1h , m ), 7 . 75 ( 2h , d , j = 8 . 7 hz ), 7 . 80 ( 1h , s ), 7 . 82 ( 1h , s ), 8 . 17 ( 1h , d , j = 8 . 7 hz ), 8 . 66 ( 1h , s ), 8 . 77 ( 1h , brs ). δ : 1 . 05 ( 3h , d , j = 6 . 5 hz ), 1 . 50 ( 9h , s ), 4 . 41 ( 1h , d , j = 14 . 3 hz ), 5 . 49 ( 1h , d , j = 13 . 3 hz ), 5 . 92 ( 1h , s ), 6 . 73 - 6 . 82 ( 3h , m ), 7 . 30 - 7 . 38 ( 1h , m ), 7 . 63 - 8 . 01 ( 7h , m ), 8 . 85 ( 1h , brs ). δ : 1 . 05 ( 3h , d , j = 6 . 5 hz ), 1 . 51 ( 9h , s ), 3 . 29 - 3 . 35 ( 8h , m ), 4 . 44 ( 1h , d , j = 14 . 5 hz ), 5 . 56 ( 1h , d , j = 13 . 6 hz ), 5 . 79 ( 1h , s ), 6 . 73 - 6 . 79 ( 3h , m ), 6 . 89 ( 2h , d , j = 9 . 0 hz ), 6 . 97 ( 2h , d , j = 8 . 9 hz ), 7 . 20 - 7 . 34 ( 5h , m ), 7 . 79 ( 1h , s ), 7 . 81 ( 1h , s ), 8 . 49 ( 1h , s ). δ : 1 . 05 ( 3h , d , j = 6 . 3 hz ), 1 . 51 ( 9h , s ), 2 . 96 ( 6h , s ), 4 . 45 ( 1h , d , j = 14 . 4 hz ), 5 . 60 ( 1h , d , j = 12 . 7 hz ), 5 . 71 ( 1h , s ), 6 . 71 - 6 . 79 ( 5h , m ), 7 . 22 - 7 . 25 ( 2h , m ), 7 . 30 - 7 . 38 ( 1h , m ), 7 . 79 ( 1h , s ), 7 . 82 ( 1h , s ), 8 . 45 ( 1h , brs ). δ : 1 . 1 ( 3h , m ), 1 . 56 ( 9h , s ), 4 . 56 ( 1h , s ), 5 . 66 ( 1h , d , j = 14 . 6 hz ), 5 . 87 ( s , 1h ), 6 . 73 - 6 . 79 ( 3h , m ), 7 . 36 - 7 . 38 ( 1h , m ), 7 . 52 - 7 . 62 ( 5h , m ), 7 . 84 - 7 . 91 ( 4h , m ), 8 . 13 ( 1h , brs ), 8 . 75 ( 1h , brs ). δ : 0 . 85 - 0 . 89 ( 3h , m ), 0 . 99 ( 3h , d , j = 6 . 6 hz ), 1 . 26 ( 10h , m ), 1 . 51 ( 9h , s ), 3 . 55 ( 1h , b s ), 3 . 75 - 3 . 79 ( 1h , m ), 4 . 31 ( 1h , d , j = 14 . 9 hz ), 5 . 57 ( 1h , d , j = 14 . 2 hz ), 5 . 68 ( s , 1h ), 6 . 63 - 6 . 65 ( 1h , m ), 6 . 70 - 6 . 79 ( 2h , m ), 6 . 91 ( 1h , brs ), 7 . 29 - 7 . 35 ( 1h , m ), 7 . 77 ( 1h , s ), 7 . 81 ( 1h , s ). δ : 1 . 02 ( 3h , d , j = 7 . 5 hz ), 1 . 49 ( 9h , s ), 1 . 54 ( 9h , s ), 4 . 31 ( 1h , d , j = 13 . 9 hz ), 5 . 46 ( 1h , d , j = 14 . 2 hz ), 5 . 64 ( 1h , s ), 6 . 73 - 6 . 79 ( 2h , m ), 7 . 31 - 7 . 34 ( 1h , m ), 7 . 83 ( 1h , s ), 7 . 86 ( 1h , s ) δ : 1 . 01 ( 3h , d , j = 6 . 9 hz ), 1 . 5 ( 9h , s ), 3 . 8 ( 3h , s ), 4 . 36 ( 1h , d , j = 14 . 4 hz ), 4 . 58 ( 2h , s ), 5 . 39 ( 1h , d , j = 14 . 6 hz ), 5 . 74 ( 1h , s ), 6 . 56 - 6 . 71 ( 1h , m ), 6 . 73 - 6 . 79 ( 2h , m ), 7 . 3 - 7 . 32 ( 1h , s ), 7 . 35 - 7 . 4 ( 1h , m ), 7 . 77 ( 1h , s ), 7 . 80 ( 1h , s ). δ : 1 . 01 ( 3h , d , j = 7 . 0 hz ), 1 . 44 ( 9h , s ), 3 . 78 ( 3h , s ), 4 . 43 ( 1h , d , j = 14 . 4 hz ), 5 . 53 ( 1h , d , j = 14 . 5 hz ), 5 . 77 ( 1h , s ), 6 . 15 ( 1h , brs ), 6 . 53 - 6 . 57 ( 1h , m ), 6 . 72 - 6 . 77 ( 2h , m ), 7 . 32 - 7 . 46 ( 4h , m ), 7 . 70 - 7 . 73 ( 1h , m ), 7 . 80 ( 1h , s ), 7 . 83 ( 1h , s ). δ : 0 . 05 ( 6h , s ), 0 . 88 ( 9h , s ), 1 . 01 ( 3h , d , j = 6 . 5 hz ), 1 . 48 ( 9h , s ), 3 . 72 ( 3h s ,), 3 . 94 - 3 . 97 ( 1h , s ), 4 . 18 - 4 . 21 ( 1h , m ), 4 . 39 - 4 . 44 ( 1h , m ), 5 . 26 - 5 . 30 ( 1h , m ), 5 . 52 - 5 . 57 ( 1h , m ), 5 . 75 ( 1h , s ), 6 . 58 - 6 . 6 ( 1h , m ), 6 . 73 - 6 . 78 ( 2h , m ), 7 . 31 - 7 . 36 ( 2h , m ), 7 . 71 - 7 . 74 ( 2h , m ), 7 . 77 ( 1h , s ), 7 . 8 ( 1h , s ) δ : 0 . 99 ( 3h , d , j = 6 . 36 hz ), 1 . 49 ( 9h , s ), 2 . 02 - 2 . 04 ( 2h , m ), 2 . 10 ( 3h , s ), 2 . 55 - 2 . 6 ( 2h , m ) 3 . 76 ( 3h , s ), 4 . 34 ( 1h , d , j = 14 . 4 hz ), 5 . 26 - 5 . 32 ( 1h , m ), 5 . 49 ( 1h , d , j = 14 . 4 hz ), 5 . 74 ( 1h , s ), 6 . 55 - 6 . 57 ( 1h , m ), 6 . 7 - 6 . 78 ( 2h , m ), 7 . 3 - 7 . 32 ( 1h , m ), 7 . 56 ( 1h , brs ), 7 . 71 ( 1h , brs ), 7 . 77 ( 1h , s ), 7 . 79 ( 1h , s ). δ : 1 . 03 ( 3h , d , j = 6 . 0 hz ), 1 . 23 - 1 . 31 ( 3h , m ), 1 . 52 ( 9h , s ), 3 . 31 - 3 . 32 ( 2h , m ), 4 . 12 - 4 . 19 ( 2h , m ), 4 . 32 ( 1h , d , j = 15 hz ), 5 . 46 - 5 . 57 ( 2h , m ), 5 . 73 ( 1h , s ), 6 . 61 - 6 . 63 ( 1h , m ), 6 . 72 - 6 . 77 ( 2h , m ), 7 . 20 - 7 . 22 ( 2h , m ), 7 . 42 - 7 . 44 ( 1h , m ), 7 . 65 ( 1h , brs ), 7 . 77 ( 1h , s ), 7 . 8 ( 1h , s ) δ : 0 . 94 - 1 . 01 ( 9h , m ), 1 . 48 ( 9h , s ), 1 . 64 - 1 . 77 ( 3h , m ), 3 . 72 ( 3h , s ), 4 . 34 ( 1h , d , j = 14 . 4 hz ), 5 . 11 - 5 . 16 ( 1h , m ), 5 . 48 ( 1h , d , j = 14 . 5 hz ), 5 . 73 ( 1h , s ), 6 . 54 - 6 . 59 ( 1h , m ), 6 . 70 - 6 . 77 ( 2h , m ), 7 . 12 ( 1h , brs ), 7 . 29 - 7 . 34 ( 1h , m ), 7 . 76 ( 1h , s ), 7 . 78 ( 1h , s ). 1 h nmr ( cdcl 3 ): δ 1 . 00 ( d , j = 6 . 90 hz , 3h , chch 3 ), 1 . 44 ( bs , 9h , boc — h ), 4 . 32 ( d , j = 14 . 42 hz , 1h , ch 2 - triazole ), 4 . 89 ( bs , 2h , ch 2 - furan ), 5 . 53 ( d , j = 14 . 21 hz , 1h , ch 2 - triazole ), 5 . 70 ( bs , 1h , d 2 o - exchangeable , — oh ), 6 . 33 ( bs , 2h , furan - h ), 6 . 61 - 6 . 64 ( m , 1h , chch 3 ), 6 . 70 - 6 . 79 ( m , 2h , arf 2 — h ), 7 . 29 - 7 . 35 ( m , 1h , 1h of furan ), 7 . 76 ( s , 1h , triazole - h ), 7 . 80 ( s , 1h , triazole - h ) 1 h nmr ( cdcl 3 ): δ 1 . 03 ( d , j = 6 . 85 hz , 3h , chch 3 ), 1 . 46 ( bs , 9h , boc — h ), 3 . 51 ( bs , 1h , d 2 o - exchangeable , — nh ), 4 . 36 ( d , j = 14 . 45 hz , 1h , ch 2 - triazole ), 5 . 07 ( bs , 2h , ch 2 - thiophene ), 5 . 59 ( d , j = 14 . 59 hz , 1h , ch 2 - triazole ), 5 . 73 ( bs , 1h , d 2 o - exchangeable , — oh ), 6 . 65 - 6 . 67 ( m , 1h , chch 3 ), 6 . 73 - 6 . 82 ( m , 2h , arf 2 — h ), 6 . 97 - 7 . 00 ( m , 1h , thiophene - h ), 7 . 07 ( bs , 2h , thiophene - h ), 7 . 24 - 7 . 36 ( m , 2h , 1h of thiophene and 1h of arf 2 ), 7 . 63 ( bs , 1h , d 2 o - exchangeable , — nh ), 7 . 79 ( s , 1h , triazole - h ), 7 . 84 ( s , 1h , triazole - h ) δ : 0 . 99 ( 3h , d , j = 5 . 6 hz ), 1 . 51 ( 9h , s ), 4 . 35 ( 1h , d , j = 13 . 9 hz ), 5 . 2 ( 1h , d , j = 13 . 7 hz ), 5 . 4 ( 1h , brs ), 5 . 59 ( 1h , brs ), 6 . 73 - 6 . 79 ( 2h , m ), 7 . 18 - 7 . 48 ( 5h , m ), 7 . 54 ( 1h , brs ), 7 . 76 ( 2h , s ). δ : 1 . 51 ( s , 9h ), 4 . 32 ( t , j = 11 . 2 hz , 3h ) 5 . 21 ( d , 11 . 4 hz , 1h ), 5 . 40 ( brs , 1h ), 5 . 57 ( brs , 1h ), 6 . 06 ( tt , j = 5 . 34 & amp ; 4 . 8 hz , 1h ), 6 . 73 - 6 . 79 ( m , 2h ), 6 . 88 - 6 . 91 ( m , 2h ), 7 . 26 - 7 . 43 ( m , 4h ), 7 . 76 ( s , 1h ) δ : 1 . 00 ( 3h , d , j = 6 . 3 hz ), 1 . 53 ( 9h , s ), 3 . 79 ( 3h , s ), 4 . 4 ( 1h , d , j = 14 . 5 hz ), 5 . 25 ( 1h , d , j = 13 . 4 hz ), 5 . 51 - 5 . 52 ( 1h , m ), 6 . 47 - 6 . 49 ( 2h , m ), 6 . 73 - 6 . 79 ( 2h , m ), 7 . 31 - 7 . 35 ( 1h , m ), 7 . 75 ( 2h , m ), 7 . 87 ( 1h , s ), 8 . 05 ( 1h , d , j = 7 . 0 hz ). δ : 1 . 06 ( d , j = 7 . 0 hz , 3h ), 4 . 63 ( d , j = 14 . 3 hz , 1h ), 5 . 24 ( d , j = 14 . 3 hz , 1h ), 5 . 30 ( m , 1h ), 6 . 72 - 6 . 83 ( m , 2h ), 7 . 24 - 7 . 34 ( m , 2h ), 7 . 45 - 7 . 47 ( d , j = 8 . 8 hz , 2h ), 7 . 84 ( s , 1h ), 8 . 51 ( brs , 1h ), 8 . 91 ( s , 1h ). to a solution of compound no 1 ( 3 . 5 g in dichloromethane ( 30 ml ) at 0 ° c . was slowly added a solution of trifluoroacetic acid in dichloromethane ( 30 ml , 30 % v / v ) and the reaction mixture was stirred at 0 ° c . temperature for 2 h . after the completion of reaction , the solvents were evaporated and the residue dissolved in dichloromethane . the organic layer was washed with 5 % nahco 3 till no more effervescence was observed . the organic layer was washed with water , brine and dried over na 2 so 4 . the solvent was removed in vacuo and the residue purified through column chromatography ( silica gel , 100 - 200 mesh , 10 % etoac - dcm ) to afford the title compound ( 1 . 81 g , 61 %). 1 h nmr ( 300 mhz , cdcl 3 ): δ1 . 12 ( d , j = 7 . 0 hz , 3h ), 4 . 35 ( t , j = 11 . 8 hz , 2h ), 4 . 48 ( d , j = 14 . 6 hz , 1h ), 4 . 55 ( s , 2h ), 5 . 60 ( d , j = 14 . 6 hz , 1h ), 5 . 65 ( s , 1h ), 6 . 06 ( tt , j = 53 . 1 and 4 . 9 hz , 1h ), 6 . 64 ( q , j = 6 . 6 hz , 1h ), 6 . 73 - 6 . 80 ( m , 2h ), 6 . 94 ( d , j = 8 . 9 hz , 2h ), 7 . 33 - 7 . 36 ( m , 1h ), 7 . 46 ( d , j = 8 . 9 hz , 2h ), 7 . 79 ( s , 1h ), 7 . 83 ( s , 1h ), 9 . 94 ( s , 1h ). the illustrative list of the compounds of the invention which were synthesized by the above method is given below : δ : 1 . 11 ( 3h , d , j = 6 . 9 hz ), 3 . 49 ( 1h , s ), 4 . 62 ( 1h , d , j = 14 . 7 hz ), 5 . 60 ( 1h , d , j = 14 . 5 hz ), 6 . 66 - 6 . 82 ( 3h , m ), 7 . 18 - 7 . 23 ( 1h , m ), 7 . 31 - 7 . 39 ( 3h , m ), 7 . 57 - 7 . 59 ( 2h , m ), 7 . 82 ( 1h , s ), 8 . 36 ( 1h , brs ), 10 . 1 ( 1h , brs ). δ : 0 . 94 ( 3h , d , j = 6 . 9 hz ), 4 . 51 ( 1h , d , j = 14 . 5 hz ), 5 . 10 ( 1h , d , j = 14 . 5 hz ), 6 . 51 ( 3h , q , j = 6 . 9 hz ), 6 . 71 ( 2h , d , j = 8 . 7 hz ), 6 . 89 - 6 . 95 ( 1h , m ), 7 . 14 - 7 . 25 ( 4h , m ), 7 . 66 ( 1h , s ), 8 . 31 ( 1h , s ), 9 . 98 ( 1h , brs ). δ : 1 . 11 ( 3h , d , j = 6 . 9 hz ), 3 . 81 ( 3h , s ), 3 . 83 ( 3h , s ), 4 . 49 ( 1h , d , j = 14 . 7 hz ), 4 . 53 ( 2h , s ), 5 . 58 ( 1h , s ), 5 . 64 ( 1h , d , j = 14 . 3 hz ), 6 . 51 - 6 . 54 ( 2h , m ), 6 . 66 - 6 . 68 ( 1h , m ), 6 . 76 - 6 . 8 ( 2h , m ), 7 . 35 - 7 . 38 ( 1h , m ), 7 . 78 ( 1h , s ), 7 . 84 ( 1h , s ), 8 . 18 ( 1h , d , j = 8 . 5 hz ), 10 . 1 ( 1h , s ). δ : 1 . 13 ( 3h , d , j = 6 . 9 hz ), 4 . 46 ( 1h , d , j = 14 . 4 hz ), 4 . 62 ( 2h , s ), 5 . 57 ( 1h , d , j = 14 . 6 hz ), 5 . 7 ( 1h , s ), 6 . 66 - 6 . 8 ( 1h , m ), 6 . 77 - 6 . 82 ( 2h , m ), 7 . 32 - 7 . 38 ( 1h , d , 7 . 61 - 7 . 63 ( 2h , m ), 7 . 66 - 7 . 7 ( 2h , m ), 7 . 8 ( 1h , s ), 7 . 84 ( 1h , s ), 10 . 34 ( 1h , s ). 1 h nmr ( cdcl 3 ): δ 1 . 14 ( d , j = 6 . 93 hz , 3h , chch 3 ), 4 . 48 ( d , j = 15 . 00 hz , 1h , ch 2 - triazole ), 4 . 62 ( bs , 2h , nh 2 ), 5 . 61 ( d , j = 15 . 00 hz , 1h , ch 2 - triazole ), 5 . 70 ( bs , 1h , d 2 o - exchangeable , — oh ), 6 . 64 - 6 . 68 ( m , 1h , chch 3 ), 6 . 77 - 6 . 84 ( m , 2h , arf 2 — h ), 7 . 20 - 7 . 29 ( m , 2h , arocf 3 - h ), 7 . 34 - 7 . 42 ( m , 1h , arf 2 — h ), 7 . 66 ( d , j = 9 . 00 hz , 2h , arocf 3 — h ), 7 . 82 ( s , 1h , triazole - h ), 7 . 86 ( s , 2h , triazole - h ), 10 . 17 ( s , 1h , nh ) 1 h nmr ( cdcl 3 ; 300 mhz ) : δ : 1 . 05 ( d , j = 6 . 9 hz , 3h , ch — ch 3 ), 4 . 33 - 4 . 41 ( m , 3h , 1h of ch 2 triazole and nh 2 ), 4 . 86 ( d , j = 5 . 1 hz , 2h , ch 2 furan ), 5 . 54 - 5 . 59 ( m , 2h , 1h of ch 2 triazole and oh ), 6 . 32 - 6 . 34 ( m , 2h , furan - h ), 6 . 52 ( q , 1h , j = 6 . 6 hz , ch — ch 3 ) 6 . 71 - 6 . 79 ( m , 2h , arf 2 ), 7 . 77 ( s , 1h , triazole — h ), 7 . 84 ( s , 1h , triazole — h ), 8 . 43 ( brs , 1h , d 2 o - exchangeable — nh ). 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 1 . 05 ( d , j = 6 . 9 hz , 3h , ch — ch 3 ), 4 . 32 ( brs , 2h , d 2 o - exchangeable , nh 2 ), 4 . 39 ( d , j = 14 . 7 hz , 1h ch 2 - triazole ), 5 . 04 ( abq , j = 15 . 3 hz , 13 . 05 hz , 2h , ch 2 - thiophene ), 5 . 54 ( brs , 1h , d 2 o exchangaeable — oh ), 5 . 59 ( d , j = 14 . 4 hz , 1h , ch 2 - triazole ), 6 . 50 - 6 . 54 ( m , 1h , ch — ch 3 ), 6 . 72 - 6 . 80 ( m , 2h , arf 2 — h ), 6 . 95 - 6 . 98 ( m , 1h , thiophene - h ), 7 . 05 ( brs , 1h , thiophene - h ), 7 . 22 - 7 . 37 ( m , 2h , 1h of thiopene + 1h of arf 2 — h ), 7 . 76 ( s , 1h , triazole - h ), 7 . 84 ( s , 1h , triazole - h ), 8 . 45 ( s , 1h , d 2 o - exchangeable — nh ) 1 h nmr ( cdcl 3 ): δ 1 . 11 ( d , j = 6 . 90 hz , 3h , chch 3 ), 4 . 43 ( d , j = 14 . 37 hz , 1h , ch 2 - triazole ), 4 . 64 ( bs , 2h , — nh 2 ), 5 . 55 ( d , j = 14 . 37 hz , 1h , ch 2 - triazole ), 5 . 70 ( bs , 1h , d 2 o - exchangeable , — oh ), 6 . 64 - 6 . 67 ( m , 1h , chch 3 ), 6 . 74 - 6 . 81 ( m , 2h , arf 2 — h ), 7 . 31 - 7 . 36 ( m , 1h , arf 2 — h ), 7 . 66 - 7 . 70 ( m , 1h , pyridine - h ), 7 . 77 ( s , 1h , triazole - h ), 7 . 82 ( s , 1h , triazole - h ), 8 . 27 ( bs , 1h , pyridine - h ), 8 . 90 ( d , j = 8 . 91 hz , 1h , pyridine - h ), 10 . 86 ( bs , 1h , nh ) 1 h nmr ( cdcl 3 ): δ 1 . 14 ( d , j = 6 . 93 hz , 3h , chch 3 ), 4 . 49 ( d , j = 14 . 46 hz , 1h , ch 2 - triazole ), 4 . 74 ( bs , 2h , nh 2 ), 5 . 59 ( d , j = 14 . 58 hz , 1h , ch 2 - triazole ), 5 . 74 ( bs , 1h , d 2 o - exchangeable , — oh ), 6 . 65 - 6 . 67 ( m , 1h , chch 3 ), 6 . 74 - 6 . 81 ( m , 2h , arf 2 — h ), 7 . 30 - 7 . 40 ( m , 1h , arf 2 — h ), 7 . 79 ( s , 1h , triazole - h ), 7 . 83 ( s , 1h , triazole - h ), 7 . 99 ( s , 1h , pyridine - h ), 8 . 72 ( s , 1h , pyridine - h ), 10 . 72 ( bs , 1h , nh ), 1 h nmr ( dmso - d 6 ): δ 1 . 01 ( d , j = 6 . 67 hz , 3h , chch 3 ), 4 . 59 ( d , j = 14 . 37 hz , 1h , ch 2 - triazole ), 5 . 15 ( d , j = 14 . 58 hz , 1h , ch 2 - triazole ), 6 . 33 ( bs , 1h , d 2 o - exchangeable — oh ), 6 . 52 - 6 . 54 ( m , 1h , chch 3 ), 6 . 92 - 6 . 97 ( m , 1h , arf2h ), 7 . 30 - 7 . 17 ( m , 2h , arf 2 — h ), 7 . 58 - 7 . 63 ( m , 1h , quinoline - h ), 7 . 68 - 7 . 74 ( m , 2h , quinoline - h ), 7 . 96 - 8 . 01 ( m , 2h , 1h of triazole and 1h of quinoline ), 8 . 31 ( s , 1h , triazole — h ), 8 . 60 ( s , 1h , quinoline - h ), 9 . 00 ( s , 1h , quinoline - h ) method i : a solution of compound no . 24 ( 280 mg ) in formic acid ( 0 . 6 ml ) was - refluxed for 2 hours . after the completion of reaction , the reaction mixture was poured in ice cold water and neutralized with nahco 3 . the organic layers were extracted into etoac , washed with water and dried over naso 4 . solvent was s removed in vacuo and the residue purified through column chromatography ( silica gel , 100 - 200 mesh , 50 % etoac - dcm ) to afforded title compound ( 200 mg , 70 %). method ii : a solution of compound no . 1 ( 300 mg ) in formic acid ( 2 ml ) was refluxed for 1 . 5 hours . after completion of reaction , the reaction mixture was poured into ice cold water and neutralised with nahco 3 . the organic layers were extracted with ethyl acetate and washed with water and dried over na 2 so4 . solvent was removed in vacuo and the residue purified through column chromatography ( silica gel , 100 - 200 mesh , 50 % etoac - dcm ) to afforded title compound , 121 mg ( 50 %) 1 h nmr ( 300 mhz , cdcl 3 ): δ1 . 33 ( d , j = 6 . 9 hz , 3h ), 4 . 34 - 4 . 46 ( m , 3h ), 5 . 13 ( d , j = 14 . 4 hz , 1h ), 5 . 21 ( s , 1h ), 5 . 88 - 5 . 96 ( m , 1h ), 6 . 06 ( tt , j = 48 . 5 and 4 . 6 hz , 1h ), 6 . 82 - 6 . 88 ( m , 2h ), 7 . 09 - 7 . 12 ( m , 2h ), 7 . 53 - 7 . 65 ( m , 3h ), 7 . 74 ( s , 1h ), 7 . 93 ( s , 1h ). the illustrative list of the compounds of the invention which were synthesized by the above method is given below : 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 1 . 35 ( 3h , d , j = 6 . 9 hz ), 4 . 43 ( 1h , d , j = 14 . 3 hz ), 5 . 07 ( 1h , d , j = 14 . 3 hz ), 5 . 23 ( 1h , s ), 5 . 94 ( 1h , q , j = 7 . 08 hz ), 6 . 82 - 6 . 89 ( 2h , m ), 7 . 59 - 7 . 67 ( 1h , m ), 7 . 76 ( 1h , s ), 7 . 89 - 8 . 02 ( 4h , m ), 8 . 25 ( 1h , s ), 9 . 0 ( 1h , s ) 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 1 . 19 ( 3h , d , j = 6 . 9 hz ), 4 . 28 ( 1h , d , j = 14 . 4 hz ), 5 . 09 ( 2h , d , j = 14 . 5 hz ), 5 . 74 - 5 . 80 ( 2h , m ), 6 . 90 - 6 . 95 ( 3h , m ), 7 . 18 - 7 . 35 ( 2h , m ), 7 . 43 ( 2h , d , j = 8 . 64 hz ), 7 . 59 ( 1h , s ), 8 . 30 ( 1h , s ), 8 . 88 ( 1h , s ), 9 . 97 ( 1h , s ). 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 1 . 27 ( 3h , d , j = 7 . 2 hz ), 4 . 42 ( 1h , d , j = 14 . 3 hz ), 5 . 11 ( 1h , d , j = 14 . 3 hz ), 5 . 21 ( 1h , s ), 5 . 89 - 5 . 95 ( 1h , s ), 6 . 82 - 6 . 88 ( 2h , m ), 7 . 58 - 7 . 64 ( 1h , m ), 7 . 75 ( 1h , s ), 7 . 89 ( 1h , s ), 7 . 91 - 7 . 93 ( 2h , m ), 8 . 01 ( 1h , s ), 8 . 44 ( 1h d , j = 8 . 6 hz ). 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 1 . 36 ( 3h , d , j = 6 . 9 hz ), 4 . 42 ( 1h , d , j = 14 . 4 hz ), 5 . 14 ( 1h , d , j = 14 . 1 hz ), 5 . 22 ( 1h , s ), 5 . 94 - 5 . 99 ( 1h , m ), 6 . 79 - 6 . 89 ( 2h , m ), 7 . 53 - 7 . 68 ( 1h , m ), 7 . 74 ( 1h , s ), 7 . 77 - 7 . 86 ( 2h , m ), 7 . 89 ( 1h , s ), 7 . 95 ( 1h , s ), 8 . 40 ( 2h , d , j = 8 . 9 hz ), 8 . 72 ( 1h , s ). 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 1 . 35 ( 3h , d , j = 6 . 9 hz ), 4 . 4 ( 1h , d , j = 14 . 5 hz ), 5 . 13 ( 1h , d , j = 14 . 2 hz ), 5 . 21 ( 1h , s ), 5 . 93 - 5 . 95 ( 1h , m ), 6 . 82 - 6 . 88 ( 2h , m ), 7 . 58 - 7 . 63 ( 1h , s ), 7 . 75 ( 1h , s ), 7 . 77 - 7 . 87 ( 5h , m ), 7 . 93 ( 1h , s ), 7 . 98 ( 1h , s ). 1 h nmr ( cdcl 3 ): δ 7 . 96 ( s , 2h , triazole - h ), 7 . 75 ( s , 1h , thio - triazolone - h ), 7 . 68 - 7 . 57 ( m , 3h , 1h of arf 2 and 2h of arocf 3 ), 7 . 41 ( d , 2h , j = 8 . 46 hz , 2h of arocf 3 ), 6 . 88 - 6 . 82 ( m , 2h , 2h of arf 2 ), 5 . 93 ( q , 1h , j = 6 . 96 hz , chch 3 ), 5 . 20 ( bs , 1h , d 2 o - exchangeable , — oh ), 5 . 13 ( d , 1h , j = 14 . 37 hz , ch 2 - triazole ), 4 . 38 ( d , 1h , j = 14 . 28 hz , ch 2 - triazole ), 1 . 33 ( d , 3h , j = 6 . 93 hz , chch 3 ) δ : 1 . 34 ( 3h , d , j = 6 . 8 hz ), 4 . 41 ( 1h , d , j = 14 . 3 hz ), 5 . 12 ( 1h , d , j = 14 . 3 hz ), 5 . 22 - 5 . 29 ( 1h , m ), 5 . 93 ( 1h , q , j = 6 . 9 hz ), 6 . 83 - 6 . 89 ( 2h , m ), 7 . 58 - 7 . 67 ( 1h , m ), 7 . 76 ( 1h , s ), 7 . 82 - 7 . 90 ( 4h , m ), 7 . 93 ( 1h , s ), 7 . 99 ( 1h , s ). 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 1 . 25 ( 3h , d , j = 6 . 9 hz ), 3 . 79 ( 3h , s ), 4 . 04 ( 1h , d , j = 14 . 3 hz ), 4 . 87 ( 2h , q , 17 . 7 hz ), 4 . 98 ( 1h , d , 14 . 3 hz ), 5 . 81 - 5 . 83 ( 1h , m ), 6 . 78 - 6 . 84 ( 2h , m ), 7 . 50 - 7 . 56 ( 1h , m ), 7 . 71 ( 1h , s ), 7 . 89 ( 1h , s ), 8 . 03 ( 1h , s ). methyl - 2 - hydroxymethyl - 2 -[[( 1r , 2r )- 2 -( 2 , 4 - difluorophenyl )- 2 - hydroxy - 1 - methyl - 3 -( 1h - 1 , 2 , 4 - triaolyl ) propyl ]-( 2h , 4h )- 1 , 2 , 4 - triazol - 3 - thion - 4 - yl ] acetate ( compound no . 49 ) [ 1 : 1 mixture of diasteromers at c - 2 ] 1 h nmr ( cdcl 3 ; 300 mhz ): δ 0 . 95 ( 3h , d , j = 6 . 6 hz ), 1 . 31 ( 3h , d , j = 7 . 0 hz ), 3 . 56 - 3 . 59 ( 2h , m ), 3 . 74 - 3 . 82 ( 2h , m ), 3 . 84 ( 3h , s ), 3 . 88 ( 3h , s ), 4 . 06 ( 1h , d , j = 14 . 3 hz ), 4 . 4 - 4 . 49 ( 1h , m ), 4 . 5 - 4 . 6 ( 1h , m ), 5 . 0 - 5 . 18 ( 3h , m ), 5 . 3 - 5 . 45 ( 1h , m ), 5 . 82 ( 1h , q , j = 7 . 0 hz ), 6 . 05 ( 1h , brs ), 6 . 78 - 6 . 84 ( 4h , m ), 6 . 98 ( 1h , s ), 7 . 49 - 7 . 6 ( 1h , m ), 7 . 69 ( 1h , s ), 7 . 71 ( 1h , s ), 7 . 83 ( 1h , s ), 7 . 87 ( 1h , s ), 8 . 08 ( 1h , s ), 8 . 25 ( 1h , s ) 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 0 . 90 ( 3h , d , j = 6 . 7 hz ), 1 . 22 ( 3h , d , j = 7 . 4 hz ), 3 . 77 ( 3h , s ), 3 . 86 ( 3h , s ), 4 . 05 ( 1h , d , j = 14 . 4 hz ), 4 . 53 ( 1h , d , j = 15 . 1 hz ), 4 . 86 ( 1h , d , j = 15 . 1 hz ), 5 . 18 ( 1h , d , j = 14 . 5 hz ), 5 . 84 ( 1h , q , j = 6 . 9 hz ), 6 . 35 - 6 . 45 ( 1h , m ), 6 . 59 ( 1h , s ), 6 . 79 - 6 . 82 ( 2h , m ), 6 . 90 - 7 . 0 ( 2h , m ), 7 . 05 ( 1h , s ), 7 . 1 - 7 . 25 ( 1h , m ), 7 . 38 - 7 . 50 ( 10h , m ), 7 . 70 - 7 . 74 ( 3h , m ), 7 . 82 ( 1h , s ), 7 . 88 ( 1h , s ) 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 0 . 92 - 1 . 04 ( 12h , m ), 1 . 25 - 1 . 31 ( 6h , m ), 1 . 53 - 1 . 59 ( 2h , m ), 1 . 73 - 1 . 78 ( 2h , m ), 1 . 79 - 2 . 00 ( 1h , m ), 2 . 04 - 2 . 09 ( 1h , m ), 3 . 78 ( 3h , s ), 3 . 82 ( 3h , s ), 4 . 01 ( 1h , d , j = 14 . 4 hz ), 4 . 47 ( 1h , d , j = 15 . 0 hz ), 4 . 83 ( 1h , d , j = 15 . 2 hz ), 5 . 11 - 5 . 19 ( 2h , m ), 5 . 60 - 5 . 75 ( 1h , m ), 5 . 85 - 5 . 95 ( 1h , m ), 6 . 20 - 6 . 49 ( 1h , m ), 6 . 81 - 6 . 85 ( 3h , m ), 6 . 9 - 7 . 0 ( 1h , m ), 7 . 05 ( 1h , s ), 7 . 19 - 7 . 21 ( 1h , m ), 7 . 45 - 7 . 55 ( 1h , m ), 7 . 69 ( 1h , s ), 7 . 70 ( 1h , s ), 7 . 73 ( 1h , s ), 7 . 87 ( 1h , s ), 8 . 08 ( 1h , s ) 1 h nmr ( cdcl 3 ; 300 mhz ): δ : 0 . 93 ( 3h , d , j = 6 . 6 hz ), 1 . 31 ( 3h , d , j = 6 . 9 hz ), 2 . 12 ( 6h , s ), 3 . 81 ( 3h , s ), 3 . 84 ( 3h , s ), 4 . 04 ( 1h , d , j = 14 . 4 hz ), 4 . 47 ( 1h , d , j = 15 . 1 hz ), 4 . 83 ( 1h , d , j = 15 . 1 hz ), 5 . 06 ( 1h , brs ), 5 . 16 ( 1h , d , j = 14 . 3 hz ), 5 . 25 - 5 . 30 ( 1h , m ), 5 . 74 - 5 . 77 ( 1h , m ), 5 . 84 ( 1h , q , j = 7 . 0 hz ), 6 . 36 ( 1h , q , j = 6 . 8 hz ), 6 . 78 - 6 . 85 ( 2h , m ), 6 . 92 - 6 . 93 ( 2h , m ), 7 . 07 ( 1h , s ), 7 . 50 - 7 . 56 ( 1h , m ), 7 . 70 ( 1h , s ), 7 . 73 ( 1h , s ), 7 . 87 ( 1h , s ), 8 . 13 ( 1h , s ). 1 h nmr ( cdcl 3 ): δ 7 . 78 ( s , 1h , triazole - h ), 7 . 83 ( s , 1h , triazole - h ), 7 . 67 ( s , 1h , thio - triazolone - h ), 7 . 56 - 7 . 47 ( m , 2h , 1h of furan and 1h of arf 2 ), 6 . 85 - 6 . 77 ( m , 2h , arf 2 — h ), 6 . 59 ( bs , 1h , furan - h ), 6 . 42 ( bs , 1h , furan - h ), 5 . 83 ( q , 1h , j = 6 . 91 hz , chch 3 ), 5 . 22 ( s , 2h , furan - h ), 5 . 12 ( d , 1h , j = 14 . 48 hz , ch 2 - triazole ), 5 . 07 ( bs , 1h , d 2 o - exchangeable , — oh ), 4 . 11 ( d , 1h , j = 14 . 20 hz , ch 2 - triazole ), 1 . 26 ( d , 3h , j = 6 . 94 hz , chch 3 ) 1 h nmr ( dmso - d 6 ): δ 9 . 18 ( s , 1h , quinoline - h ), 9 . 15 ( s , 1h , quinoline - h ), 8 . 77 ( s , 1h , triazole — h ), 8 . 32 ( s , 1h , triazole - h ), 8 . 17 - 8 . 12 ( m , 2h , quinoline - h ), 7 . 94 - 7 . 89 ( m , 2h , quinoline - h ) 7 . 61 ( s , 1h , thio - triazolone - 1h ), 7 . 38 - 7 . 30 ( m , 1h , arf 2 — h ), 7 . 27 - 7 . 20 ( m , 1h , arf 2 — h ), 6 . 97 - 6 . 92 ( m , 1h , arf 2 — h ), 5 . 89 ( bs , 1h , d 2 o - exchangeable , — oh ), 5 . 85 - 5 . 80 ( m , 1h , chch 3 ), 5 . 11 ( d , 1h , j = 14 . 49 hz , ch 2 - triazole ), 4 . 39 ( d , 1h , j = 14 . 40 hz , ch 2 - triazole ), 1 . 25 ( d , 3h , j = 6 . 87 hz , chch 3 ) ms (+ ve ion ): m / z 479 . 9 ( m + + 1 ) 2 -[( 1r , 2r )- 2 -( 2 , 4 - difluorophenyl )- 2 - hydroxy - 1 - methyl - 3 -( 1h - 1 , 2 , 4 - triazol - 1 - yl ) propyl ]- 4 -[ 3 - chloropyridin - 6 - yl ]-( 2h , 4h )- 1 , 2 , 4 - triazol - 3 - thione ( compound no . 55 ). 1 h nmr ( cdcl 3 ): δ 9 . 02 ( d , 1h , j = 8 . 79 hz , pyridine - h ), 8 . 72 ( s , 1h , pyridine - h ), 8 . 48 ( s , 1h , thio - triazolone - h ), 7 . 93 - 7 . 90 ( m , 2h , 1h of triazole and 1h of pyridine ), 7 . 70 ( s , 1h , triazole ), 7 . 60 - 7 . 54 ( m , 1h , arf 2 — h ), 6 . 87 - 6 . 80 ( m , 2h , arf 2 — h ), 5 . 98 ( q , 1h , j = 6 . 96 hz , chch 3 ), 5 . 17 ( d , 1h , j = 14 . 40 hz , ch 2 - triazole ), 5 . 10 ( bs , 1h , d 2 o - exchangeable , — oh ), 4 . 25 ( d , 1h , j = 14 . 28 hz , ch 2 - triazole ), 1 . 32 ( d , 3h , j = 6 . 93 hz , chch 3 ) 1 h nmr ( cdcl 3 ): δ 7 . 78 ( s , 1h , triazole - h ), 7 . 83 ( s , 1h , triazole - h ), 7 . 67 ( s , 1h , thio - triazolone - h ), 7 . 56 - 7 . 47 ( m , 2h , 1h of furan and 1h of arf 2 ), 6 . 856 . 77 ( m , 2h , arf 2 — h ), 6 . 59 ( bs , 1h , furan - h ), 6 . 42 ( bs , 1h , furan - h ), 5 . 83 ( q , 1h , j = 6 . 91 hz , chch 3 ), 5 . 22 ( s , 2h , furan - h ), 5 . 12 ( d , 1h , j = 14 . 48 hz , ch 2 - triazole ), 5 . 07 ( bs , 1h , d 2 o - exchangeable , — oh ), 4 . 11 ( d , 1h , j = 14 . 20 hz , ch 2 - triazole ), 1 . 26 ( d , 3h , j = 6 . 94 hz , chch 3 ) the compounds of the formula i and its salts are useful in the curative or prophylactic treatment of fungal infections in animals , including human . the in vitro evaluation of the antifungal activity of the compound of this invention ( as shown in table i ) can be performed by determining the minimum inhibitory concentration ( mic ) which is the concentration of the test compound in rosewell park memorial institute ( rpmi ) 1640 liquid medium buffered with 3 -( morpholino ) propane sulfonic acid ( mops ) to ph 7 , at which there is significant inhibition of the particular fungi . in practice the national committee for clinical laboratory standard ( nccls ) m27a document for candida and cryptococcus and m38p for aspergillus was used to determine the mic and readings recorded only when the quality control results fell into the acceptable range . after mic results had been recorded , 100 μl from each of the well showing no growth was spread over sabouraud dextrose agar ( sda ) to determine the minimum fungicidal concentration ( mfc ). table iii in vitro screening results of the synthesized compounds mic ( a . fum .) compound no . ( μg / ml ) 1008 si - l 1 & gt ; 16 & gt ; 16 2 & gt ; 16 & gt ; 16 3 ps - ve 4 & gt ; 16 & gt ; 16 5 & gt ; 16 & gt ; 16 6 8 8 7 4 4 8 & gt ; 16 & gt ; 16 9 & gt ; 16 & gt ; 16 10 & gt ; 16 & gt ; 16 11 ps - ve 12 0 . 25 0 . 25 13 ps - ve 14 & gt ; 16 & gt ; 16 15 & gt ; 16 & gt ; 16 16 ps - ve 17 ps - ve 18 ps - ve 19 ps - ve 20 ps - ve 21 ps - ve 22 ps - ve 23 ps - ve 24 ps - ve 25 & gt ; 16 & gt ; 16 26 & gt ; 16 & gt ; 16 27 & gt ; 16 & gt ; 16 28 & gt ; 16 & gt ; 16 29 & gt ; 16 & gt ; 16 30 & gt ; 16 & gt ; 16 31 1 0 . 25 32 & gt ; 16 & gt ; 16 33 4 2 34 2 2 35 4 4 36 4 2 37 0 . 5 1 38 ps - ve 39 16 4 40 ps - ve 41 & gt ; 16 & gt ; 16 42 0 . 25 0 . 125 43 4 2 44 2 2 45 1 0 . 5 46 2 0 . 5 47 ps - ve 48 ps - ve 49 ps - ve 50 & gt ; 16 & gt ; 16 51 & gt ; 16 & lt ; 16 52 & gt ; 16 & gt ; 16 53 8 4 54 ps - ve 55 4 2 56 ps - ve the in vivo evaluation of the compound can be carried out at a series of dose levels by oral or i . v . injection to mice which are inoculated i . v . with the minimum lethal dose of candida albicans , cryptococcus neoformans or aspergillus fumigatus by the tail vein . activity is based on the survival of a treated group of mice after the death of an untreated group of mice . for aspergillus and cryptococcus infections , target organs were cultured after treatment to document the number of mice cured of the infection for further assessment of activity . for human use , the antifungal compound of the present invention and its salts can be administered as above , but will generally by administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice for example , they can be administered orally in the form of tablets containing such excipients as starch or lactose or in capsules or ovules either alone or in admixture with exciepients or in the form of elixirs , solutions or suspensions containing flavouring or colouring agents . they can be injected parenterally , for example , intravenously , intramuscularly or sub - cutaneously . for parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances , for example , enough salts or glucose to make the solution isotonic with blood . while the present invention has been described in terms of its specific embodiments , certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention .